An innovative drug delivery platform for the benefit of patients and pharma company
LIDDS AB (publ) develops injectable drugs for cancer and other diseases based on our unique proprietary NanoZolid® technology. NanoZolid® helps solve some of the main problems with the way drugs work in the body and which affect patient quality of life. NanoZolid® enables the controlled, long-term and personalized release of drugs for up to six months. NanoZolid® can be combined with traditional small molecules as well as with larger molecules.
LIDDS has a broad range of projects where NanoZolid® is combined with cytotoxic drugs used in the treatment of cancer as well as projects in the fast-growing area of immuno-oncology. LIDDS most advanced project is Liproca® Depot, a product for local treatment of prostate cancer.
LIDDS also offers the pharmaceutical industry access to NanoZolid for their drug development projects through licensing agreements. LIDDS recently concluded a licensing agreement in China and has a number of other agreements in place. The development of these projects is subject to the research and business priorities of the licensees.
Industrial scale manufacturing is undertaken in collaboration with Recipharm. LIDDS has other development projects where NanoZolid® is combined with pharmaceutical substances, for example cytostatics and immunological drugs.
LIDDS was founded by scientists and entrepreneurs at Uppsala University, University of Gothenburg and the life science incubator PULS AB. LIDDS shares are traded on Nasdaq Stockholm First North.
Improving quality of life for patients
A key challenge in all drug development is to balance effect and safety. An effective treatment will always bring a certain risk of side-effects. Not only does this cause the patient discomfort, but in order to keep the side-effects at a manageable level it may be necessary to limit the dose of the drug to a level where it may not be as effective as desired. NanoZolid® offers a solution to this dilemma with the controlled and personalized release of active drugs, resulting in fewer side effects and less frequent injections.
Systemic treatment of severe diseases such as cancer means that very potent substances will affect several organs, not just the site of the tumor. Large parts of the body are exposed to the effects and side effects of the drug. This limits the dose and adversely affects the patient’s quality of life. LIDDS NanoZolid® technology allows the local treatment of cancer and other diseases without the serious side effects that occur with systemic treatments.
NanoZolid® controlled drug release can also be used for the treatment of systemic diseases where it is administered subcutaneously resulting in fewer treatments, increased patient compliance and reduced healthcare costs.
MESSAGE FROM THE CEO
The NanoZolid® platform is unique and constantly creates new business opportunities.
Last autumn has been an intensive time, not least after BIO-Europe, a partnering event held in Copenhagen where LIDDS met a large number of pharmaceutical company that expressed a serious interest in using the NanoZolid® technology in their drug molecules and projects.
The new patent for NanoZolid® with patent protection until 2037 gives the company’s potential licensees stronger and significantly longer protection as well as giving LIDDS the opportunity to increase royalties. The patent applies to the NanoZolid® technology and for all drug formulations developed within the framework of the technology.
One of our focus areas at BIO-Europe was NanoZolid® in combination with a STING agonist. LIDDS is currently undertaking a comprehensive preclinical program designed to attract larger licensing partners. The latest pre-clinical studies where a single injection of a NanoZolid®-STING formulation gave equal or better efficacy than three injections with a standard STING-agonist is extremely interesting. Several large pharmaceutical companies have STING-agonists in pre-clinical phases or in phase I studies, for example, Merck, Bristol-Myers Squib, Novartis and GSK. LIDDS can offer a more effective product that involves fewer treatments, demands fewer healthcare resources and reduces cancer patient suffering.
Intratumoral immunotherapy is generally sought after due to the severe and frequent side-effects when certain immune-active drugs are administered systemically, i.e. intravenously. In parallel with the STING project, LIDDS is evaluating a prioritized selection of immune-active substances. The NanoZolid® platform can be used to improve the drug’s properties, reduce side effects as well as limit the number of injections into cancer tumors. It is likely that the continual exposure achieved using NanoZolid®-formulated intratumoral immune-active substances is better or maybe even necessary to achieve good clinical effects.
During September, LIDDS commenced the second part of the phase IIb study for the treatment of prostate cancer. To maximise the inclusion rate, LIDDS has added additional urology clinics in Canada and recently contracted two large clinics in Lithuania that have many suitable patients. The LPC-004 study has been increased to 60 patients who will be followed over a period of six months. This means that the study will most likely conclude in the middle of 2019.
The Swedish Medical Products Agency has approved the phase I study for NanoZolid® combined with docetaxel. Preparations prior to the human study are ongoing and the study will be carried out at a number of Scandinavian clinics. Docetaxel is indicated for a series of different cancer tumors, which is why there are several commercial indications. This will be LIDDS second clinical project where solid tumors will be treated intratumorally.
LIDDS aim is to sign strategic partnership agreements and to license our own development projects after pre-clinical or phase I/II. The immune-oncology area is a high priority amongst research pharmaceutical companies and there are opportunities for agreements after preclinical studies.
The NanoZolid® platform is unique and constantly provides new business opportunities. Our two new project areas, NanoZolid® in combination with a STING agonist and subcutaneous depot treatment, both have significant potential and can result in new collaborations and agreements in the relatively short term.
Over the course of several years, LIDDS has developed new drug variants with a controlled intratumoral release with the aim of increasing drug effectiveness without severe systemic side effects. We have shown that the NanoZolid® technology can be used for both intratumoral and subcutaneous injectable depots which gives us an even stronger basis for a broad portfolio of drug development projects. This means both diversified risks as well as strong future royalty potential.
LIDDS places great importance on and prioritizes investment in its own development projects. The external research agreements we sign provide full cost coverage, but the decisions about continued clinical development are taken by these companies even where LIDDS meets its commitments. One example of this is the development project with Ferring Pharmaceuticals which has now concluded as Ferring has decided not to take the project further for its own company specific reasons.
Using the NanoZolid® platform, LIDDS will develop innovative and effective drugs for intratumoral treatment as well as drugs with systemic effect that are released from a subcutaneous depot. NanoZolid®-based drugs should be at least as effective as the original drug treatment but give reduced or fewer side effects and fewer treatments for patients. This is my and LIDDS goal and vision.
LIDDS enables new treatments and revitalizes existing products
LIDDS business strategy is to use the NanoZolid® technology for three purposes: In our own in-house drug development, for out- licensing to other pharmaceutical companies for use in their drug development projects, and as a tool for life cycle management of established medicines. LIDDS business model means that development lead times for NanoZolid® are significantly shorter than for traditional pharmaceutical companies.
In-house drug development
LIDDS objective is to develop pharmaceutical products in combination with NanoZolid® that are as effective as the original compounds but with fewer side effects. We aim to out-license our projects to pharmaceutical companies after the pre-clinical phases or phase I or II, subject to indications. Our most advanced project, Liproca® Depot for the treatment of prostate cancer, is currently in a Phase IIb clinical trial. LIDDS has concluded a licensing and development agreement in China for Liproca® Depot.
LIDDS has ongoing preclinical projects for cytotoxic drugs and local immunotherapy. There are also a number of other areas where the unique NanoZolid® technology can bring great benefits, including inflammatory diseases and other areas where patient compliance and convenience are drivers.
Collaborative drug development
LIDDS offers pharmaceutical companies access to NanoZolid® for their drug development projects through licensing agreements. Under these licensing agreements, LIDDS provides the NanoZolid®-based formulation for further development by our partner. The continued development of these projects is subject to the research and business priorities of the licensees.
Rejuvenating established products
With NanoZolid®, LIDDS also offers a patented solution that addresses life cycle management in the pharmaceutical industry. NanoZolid® can be used to reformulate drugs that require improvement or prolonged patent protection.
LIDDS enables new treatments and revitalizes existing products
LIDDS develops new and unique solutions to address common problems related to drugs, in particular the devastating side effects and frequent treatments that are required with pills or injections.
The NanoZolid® technology has been validated with clinical results in Phase II studies and can be used in combination with many different types of pharmaceutical molecules. As a result, our research pipeline in is broad, targeting several cancer and tumor types using both new and well-established drugs, as well as the treatment of systemic diseases where convenience and patient compliance are drivers.
LIDDS plans to out-license projects to pharmaceutical companies after the pre-clinical phases or phase I or II, subject to indications. The Liproca® Depot prostate cancer project is planned to be out-licensed after phase II whereas other projects such as solid tumor treatment with cytotoxic drugs is typically a phase I opportunity.
Following the successful pre-clinical study in immuno-oncology using a STING-agonist, LIDDS is looking to out-license NanoZolid® for this purpose as early as possible, subject to research results.
LIDDS expects a license agreement to include upfront payment, milestone payments and royalty.
Partnering with Recipharm, the GMP manufacturing process is validated in industrial scale for our prostate cancer product, Liproca® Depot.
Board directors and auditors
Chairman of the Board since 2015
Born 1960. 15 years of experience in executive roles in the pharmaceutical industry in various countries. Professor with medical background. CEO of Oncorena AB and AB Innoext. Former Vice President of Global Strategy for AstraZeneca Oncology & Infection. Professor of Physiology at the Sahlgrenska Academy, University of Gothenburg. Chairman of Glactone Pharma AB and board member of Diaprost AB. Partners in P.U.L.S. and member of the investment committee.
Holdings: 33 142 shares, 250 000 warrants
Board member since 2017
Born 1976. Master of Science in Engineering, Industrial Economy, Chalmers tekniska högskola in Gothenburg. CEO and owner of Excore AB, specialized in counseling in connection with corporate transactions in the segment of medium-sized companies. Long experience in international business. Daniel Lifveredson is engaged as a partner in several companies.
Holdings: 1 759 492 shares, 200 000 warrants
IngaLill Forslund Larsson
Board member since 2015
Born 1954. Economist with specialization in Marketing from the University of Uppsala. Leg. Midwife. Many years of sales and marketing responsibility in the pharmaceutical industry, including business responsibility for Urology, Global Marketing at Ferring Pharmaceuticals. Has held several commercial roles at AstraZeneca, among other things, responsible for a number of product launches. Senior Consultant at Lisberg Executive Search and Boyden International. CEO of a private real estate and consulting company. Board experience from several life science companies.
Holdings: 10 000 shares, 125 000 warrants
Board member since 2015
Born 1972. Master’s degree in Economics from the School of Business, Economics and Law and Concordia University, Montreal. Active as Vice President Business Development & Global Marketing at the Swedish listed company Vitrolife since 2012. Maria Forss has for 20 years worked with product development, business development and marketing of pharmaceutical products in global roles at AstraZeneca, as well as in the virtual company DuoCort, where she as CEO and project managers had been instructed to take a new drug from clinical trials to regulatory approval and sales of the company. She has experience in product development of medicines from early phase to commercialization, and from several board positions in the pharmaceutical and medical technology companies.
Holdings: 18 100 shares, 150 000 warrants
Board member since 2015
Born 1959. Professor and chief of urology at Skåne University Hospital since 2006. PhD in Medical cell research. European specialist degree in Urology. Visiting investigator at Memorial Sloan-Kettering Cancer Center in New York, 2005-2007. Associate Editor of European Urology, 2005-2012. Responsible for clinical trials in prostate cancer at the urology clinic SUS Malmö since 2007. National Principal Investigator for several new drugs for prostate cancer in recent years. Research group leader for urological cancer research at the Institute for Translational Medicine at Lund University. Published over 200 original scientific articles. H-index 39. Have experience in board work in European Urology, foundations and life science.e.
Holdings: 12 200 shares, 25 000 warrants
Mazar SET Audit agency AB
Visiting address: Järnvägsgatan 7
SE-252 24 Helsingborg
Telefon: +46 42 37 19 00
Senior executives and management
International Diploma in Marketing & Economics from University of Lund, Sweden.
Former CEO of Ellen AB (publ) from 2008 to 2014 and CEO of Probi AB (publ) 2000-2003. Senior international management positions in Pharmacia between 1986-1995. Global Category Director at Pharmacia & Upjohn during 1996-2000.
Holdings: 20 019 shares, 125 000 warrants
Accountant from the University of Uppsala. Former CFO of Know IT AB (publ), Pargon AB and AB Upnod. Bengt runs his own business Markett Affärsutveckling AB, which provides consulting services in management, economics and finance. Bengt has experience from both listed as start-ups in Life Science, IT industry and commerce. Born 1955.
Holdings: 33 274 shares, 25 000 warrants
Director of pharmaceutical R & D
Pharmacists, M.Sc. Pharm., From Uppsala University. 17 years experience in pharmaceutical research and development, including 15 years in senior services and Pharmacy Manager both Galenica AB, Malmö and Orexo AB, Uppsala, Sweden. Participated in the development of over 50 projects, of which more than a third have been upscaled to production scale and currently on the market as commercial products. Have a vast experience in solid and semi-solid drug delivery technologies. He comes from a position as Innovation Coordinator of Orexo AB. Born 1972
Holdings: 500 shares, 25 000 warrants
Director of Biomaterials & Devices
M.Sc. Engineering Physics at Uppsala University, PhD and Associate Professor of Materials Science at Uppsala University. Niklas Axen has previously worked in product development at De Beers and Hemapure, and has been in charge of R & D including Cerbio AB, Doxa AB and AB OrtoWay. Born 1963.
Holdings: 70 000 shares, 25 000 warrants
Head of preclinical R&D in immunotherapy
M.Sc. chemical engineering Lund University, Ph.D. and associate professor in organic chemistry at Lund University. 17 years of experience in medicinal chemistry and preclinical research and development. Formed Chief Scientific Officer with Respiratorius AB and senior research scientist at AstraZeneca Discovery R&D Södertälje Discovery R&D, Södertälje. Project manager for Glactone Pharma AB. Born 1971.
Holdings: 500 shares, 25 000 warrants
Head of Clinical R & D
Master of Science, M.Sc. and PhD from the Royal Institute of Technology and MBA in Project Management from Linköping Institute of Technology. About 10 years of experience as an expert in biomaterials and then 25 years experience in drug development. Has held various senior R & D positions at Pharmacia, Q-Med, Orexo, Quintiles, and BAAU Pivotal Therapeutics and helped in the development of dozens of pharmaceutical and medical device products in various indications. Born 1953.
Holdings: 25 000 warrants